- For Print
- September 1, 2017
爱豆传媒. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima®/Kisplyx® (lenvatinib mesylate, “lenvatinib”, selective inhibitor of receptor tyrosine kinases with a novel binding mode), Halaven® (eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor), and E7046 (prostaglandin E2 receptor EP4 inhibitor) will be presented during the European Society for Medical Oncology (ESMO) 2017 Congress , taking place in Madrid, Spain, from September 8 to 12, 2017.
At the ESMO 2017 Congress, there will be an oral presentation on the results of a health-related Quality of Life analysis of patients from a Phase Ⅲ clinical trial (REFLECT/Study 304) of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma, and a separate oral presentation on the results of an analysis of biomarkers from the same study. In addition, there will be an oral presentation on the results of the metastatic renal cell carcinoma cohort from a Phase Ⅰb/Ⅱ clinical trial (Study 111) of lenvatinib in combination with anti-PD-1 antibody pembrolizumab.
There are six poster presentations scheduled, including presentations on the results of a primary analysis of a Phase Ⅱ clinical trial of lenvatinib in biliary tract cancer, and the results of a Phase Ⅰ clinical trial of E7046.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
Eisai products and pipeline selected for major presentations at the ESMO 2017 Congress.
Oral Presentations:
*You can scroll to the left or right here
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
Lenvatinib Abstract No: 847O |
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma Oral Presentation | September 9 (Sat), 10:15-10:30 |
Lenvatinib Abstract No: LBA30 |
Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) |
Lenvatinib Abstract No: 618O |
Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellulcar carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR) |
Major Poster Presentations:
*You can scroll to the left or right here
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
Eribulin Abstract No: 292P |
Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin |
Lenvatinib Abstract No: 722P |
A phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results |
Lenvatinib Abstract No: 878P |
Comparing ITC results from lenvatinib plus everolimus for second-line treatment of advanced/metastatic renal cell carcinoma: Crossover versus no crossover |
Lenvatinib |
Network Meta-Analysis (NMA) of Treatments for Unresectable Hepatocellular Carcinoma (uHCC) |
Lenvatinib Abstract No: 434PD |
Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 study in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC) |
E7046 Abstract No: 373PD |
Phase 1 Study of E7046, a PGE2 Receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment |